Live
- First Star Outside Milky Way Captured: WOH G64 is 2,000 Times Larger Than the Sun
- Sikkim govt to constitute state Niti Ayog: CM Tamang
- CBI books Rajasthan narcotics inspector for Rs 3 lakh bribe
- Rajasthan bypolls: A tough contest between BJP and Congress
- Albania joins SEPA, paving way for EU integration
- Japanese government approves 250-billion USD economic package to ease price pain
- Six pharma companies to set up their units in Telangana
- The Unstable Events of a 17-Wicket Day in Perth: India vs Australia
- Dutch FM's Israel trip cancelled after Netanyahu's arrest warrant
- UK to increase energy price cap by 1.2 per cent
Dr Reddy’s plant gets FDA observations
Shares of Dr Reddys Laboratories dropped nearly 6 per cent Monday after audit of the companys formulations manufacturing plant in Hyderabad was completed by USFDA with 11 observations
Hyderabad: Shares of Dr Reddy's Laboratories dropped nearly 6 per cent Monday after audit of the company's formulations manufacturing plant in Hyderabad was completed by USFDA with 11 observations.
The company's stock tumbled 5.60 per cent to close at Rs 2,616.95 on the BSE. During the day, it tanked 7.81 per cent to Rs 2,555.55. On the NSE, shares dropped 5.57 per cent to close at Rs 2,615.35. On the volume front, 1.13 lakh shares of the company were traded on the BSE and over 18 lakh units on the NSE.
"This is to inform you that the audit of our formulations manufacturing plant- 3 at Bachupally, Hyderabad by USFDA, has been completed. We have been issued a form 483 with 11 observations," Dr Reddy's Labs said in a filing to the BSE on Friday. "We will address them comprehensively within the stipulated timeline," the filing added.
